Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share @Cosmo_Pharma #HealthCare #Earnings #Results #OTC #OTCMarkets #OTCStocks #Investing
Ad hoc announcement pursuant to Art. 53 LR Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval of GI Genius new enhanced operating system. New GI drug development program announced. Outlook for 2025. Dublin, Ireland--(Newsfile Corp. - March 20, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its preliminary unaudited results for the financial year 2023. ...
http://dlvr.it/T4KzTQ
http://dlvr.it/T4KzTQ
Comments
Post a Comment